Randomized phase II study of Gemcitabine and S-1 combination therapy versus S-1 in patients with Gemcitabine-refractory unresectable advanced Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2019
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 29 Mar 2019 Status changed from recruiting to completed.
- 20 Sep 2015 S-1(Gimeracil/oteracil/tegafur) dose range changed from 80-100 mg/day to 80-120 mg/day as reported by University Hospital Medical Information Network - Japan record.
- 23 Sep 2013 New trial record